Skip to main content
OpenTrials
Completed

NCT Number: NCT00865033

A Relative Bioavailability Study of Metformin HCL Tablets, 1000 mg Under Fasting Conditions

The purpose of this study is to demonstrate the relative bioequivalence of Metformin HCL Tablets, 1000 mg under fasting conditions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion criteria

  • Positive test results for HIV or hepatitis B or C.
  • Treatment for drug or alcohol dependence.

Treatment and study plan

Metformin HCL Tablets, 1000 mg Sandoz

Drug

Glucophage 1000 mg

Drug

Primary outcomes

  1. Bioequivalence according to US FDA guidelines

    Time frame: 9 days

Sponsors and collaborators

Lead sponsor

Sandoz

Industry

Registry information

Official study title

A Relative Bioavailability Study of Metformin HCL 1000 mg Tablets Under Fasting Conditions

Important dates

Study start
2005
Primary completion
2005
Study completion
2005
First posted
Mar 19, 2009
Registry last updated
Mar 29, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.